Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biochemistry ; 48(28): 6624-32, 2009 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-19518076

RESUMO

The epidermal growth factor receptor (EGFR) is a single-pass transmembrane protein with an extracellular ligand-binding region and a cytoplasmic tyrosine kinase. Ligand binding activates the tyrosine kinase, which in turn initiates signaling cascades that influence cell proliferation and differentiation. EGFR activity is essential for normal development of many multicellular organisms, and inappropriate activation of EGFR is associated with multiple human cancers. Several drugs targeting EGFR activity are approved cancer therapies, and new EGFR-targeted therapies are being actively pursued. Much of what is known about EGFR structure and function is derived from studies of soluble receptor fragments. We report here an approach to producing an active, membrane-spanning form of EGFR of suitable purity, homogeneity, and quantity for structural and functional studies. We show that EGFR is capable of direct autophosphorylation of tyrosine 845, which is located on its kinase activation loop, and that the kinase activity of EGFR is approximately 500-fold higher in the presence of EGF vs the inhibitory anti-EGFR antibody cetuximab. The potencies of the small molecule EGFR kinase inhibitors erlotinib and lapatinib for various forms of EGFR were measured, and the therapeutic and mechanistic implications of these results considered.


Assuntos
Receptores ErbB/antagonistas & inibidores , Receptores ErbB/metabolismo , Quinazolinas/farmacologia , Sequência de Aminoácidos , Linhagem Celular , Ativação Enzimática/efeitos dos fármacos , Receptores ErbB/química , Receptores ErbB/isolamento & purificação , Cloridrato de Erlotinib , Humanos , Cinética , Lapatinib , Dados de Sequência Molecular , Proteínas Mutantes/antagonistas & inibidores , Proteínas Mutantes/química , Proteínas Mutantes/isolamento & purificação , Proteínas Mutantes/metabolismo , Fosfopeptídeos/química , Fosforilação/efeitos dos fármacos , Fosfotirosina/metabolismo , Fatores de Tempo
2.
Biochemistry ; 47(39): 10407-19, 2008 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-18771288

RESUMO

Serotonin N-acetyltransferase [arylalkylamine N-acetyltransferase (AANAT)] is a key circadian rhythm enzyme that drives the nocturnal production of melatonin in the pineal. Prior studies have suggested that its light and diurnal regulation involves phosphorylation on key AANAT Ser and Thr residues which results in 14-3-3zeta recruitment and changes in catalytic activity and protein stability. Here we use protein semisynthesis by expressed protein ligation to systematically explore the effects of single and dual phosphorylation of AANAT on acetyltransferase activity and relative affinity for 14-3-3zeta. AANAT Thr31 phosphorylation on its own can enhance catalytic efficiency up to 7-fold through an interaction with 14-3-3zeta that lowers the substrate K m. This augmented catalytic profile is largely abolished by double phosphorylation at Thr31 and Ser205. A possible basis for this difference is the dual anchoring of doubly phosphorylated AANAT via one 14-3-3zeta heterodimer. We have developed a novel solution phase assay for accurate K D measurements of 14-3-3zeta-AANAT interaction using 14-3-3zeta fluorescently labeled with rhodamine by expressed protein ligation. We have also generated a doubly fluorescently labeled AANAT which can be used to assess the stability of this protein in a live cell, real-time assay by fluorescence resonance energy transfer measured by microscopic imaging. These studies offer new insights into the molecular basis of melatonin regulation and 14-3-3zeta interaction.


Assuntos
Arilalquilamina N-Acetiltransferase/química , Arilalquilamina N-Acetiltransferase/metabolismo , Sequência de Aminoácidos , Arilalquilamina N-Acetiltransferase/genética , Sítios de Ligação , Ritmo Circadiano , Clonagem Molecular , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Cisteína , Homeostase , Humanos , Modelos Moleculares , Dados de Sequência Molecular , Mutagênese Insercional , Fragmentos de Peptídeos/química , Conformação Proteica , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo
3.
Structure ; 16(3): 460-7, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18334220

RESUMO

HER4/ErbB4 is a ubiquitously expressed member of the EGF/ErbB family of receptor tyrosine kinases that is essential for normal development of the heart, nervous system, and mammary gland. We report here crystal structures of the ErbB4 kinase domain in active and lapatinib-inhibited forms. Active ErbB4 kinase adopts an asymmetric dimer conformation essentially identical to that observed to be important for activation of the EGF receptor/ErbB1 kinase. Mutagenesis studies of intact ErbB4 in Ba/F3 cells confirm the importance of this asymmetric dimer for activation of intact ErbB4. Lapatinib binds to an inactive form of the ErbB4 kinase in a mode equivalent to its interaction with the EGF receptor. All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. These results demonstrate that key elements of kinase activation and inhibition are conserved among ErbB family members.


Assuntos
Receptores ErbB/antagonistas & inibidores , Receptores ErbB/metabolismo , Inibidores de Proteínas Quinases/farmacologia , Animais , Células Cultivadas , Sequência Conservada , Ativação Enzimática/efeitos dos fármacos , Receptores ErbB/química , Humanos , Lapatinib , Modelos Biológicos , Modelos Moleculares , Ligação Proteica , Inibidores de Proteínas Quinases/química , Inibidores de Proteínas Quinases/metabolismo , Estrutura Quaternária de Proteína , Estrutura Secundária de Proteína , Quinazolinas/química , Quinazolinas/metabolismo , Quinazolinas/farmacologia , Receptor ErbB-2/química , Receptor ErbB-2/metabolismo , Receptor ErbB-4 , Spodoptera
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...